J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Özdemir, M.
Right arrow Articles by Rostami-Hodjegan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Özdemir, M.
Right arrow Articles by Rostami-Hodjegan, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

METHODS

Assessment of In Vivo CYP2D6 Activity: Differential Sensitivity of Commonly Used Probes to Urine pH

Mahmut Özdemir, Kim H. Crewe, Geoffrey T. Tucker and Amin Rostami-Hodjegan

From the Department of Pharmacology, Faculty of Medicine, Osmangazi University, Eskisehir, Turkey (M. Özdemir) and Molecular Pharmacology and Pharmacogenetics, University of Sheffield, United Kingdom (K. H. Crewe, G. T. Tucker, A. Rostami-Hodjegan).

Drug/metabolite ratios (MRs) are used as in vivo markers of enzyme activity. The ratios are potentially confounded by the renal clearance of the drug (urine-based MRs) or metabolite (plasma-based MRs). The authors have investigated the relative sensitivity of urinary MR of 3 in vivo probe substrates of CYP2D6 debrisoquine (DB), dextromethorphan (DM), and metoprolol (MP) to changes in urine pH. Three groups of healthy volunteers each comprising 12 individuals were given DB (10 mg), DM (25 mg), or MP (100 mg) on 3 occasions. In 1 study arm, urine was acidified by the oral intake of ammonium chloride; in another, it was alkalinized by intake of sodium bicarbonate; and in the third, urine pH was uncontrolled. Urinary MP/{alpha}-hydroxy-MP, DM/dextrorphan, and DB/4-hydroxy-DB ratios were calculated. The meangeo MR for DB was not significantly different in any of the study arms, whereas those for MP and DM were significantly different under acidified and alkalinized urine conditions compared to uncontrolled urine pH (P < .01) and were correlated with urine pH (P < .001). Without control of urine pH, in vivo estimates of CYP2D6 metabolic activity are likely to be less precise using DM or MP as probe substrates compared to DB. Although this is unlikely to cause any problem in distinguishing the large functional differences in CYP2D6 in poor metabolizer (PM) and extensive metabolizer (EM) phenotypes, this may contribute to difficulties in differentiating in vivo metabolic activity among allelic variants within the overall CYP2D6 EM phenotype using MP or DM. However, because DB is not available in many countries (eg, United States), alternative in vivo markers of CYP2D6 with low sensitivity to urine pH should be sought.


Key Words: CYP2D6phenotypingphenotype-genotype correlationdebrisoquinedextromethorphanmetoprololurine pHmetabolic ratio

Address for reprints: Dr Amin Rostami-Hodjegan, Department of Molecular Pharmacology and Pharmacogenetics, University of Sheffield, L Floor, Medicine & Pharmacology, The Royal Hallamshire Hospital, Sheffield S10 2JF UK.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
J. S. Leeder, R. E. Pearce, A. Gaedigk, A. Modak, and D. I. Rosen
Evaluation of a [13C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype
J. Clin. Pharmacol., September 1, 2008; 48(9): 1041 - 1051.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. Tomalik-Scharte, A. Jetter, M. Kinzig-Schippers, A. Skott, F. Sorgel, T. Klaassen, D. Kasel, S. Harlfinger, O. Doroshyenko, D. Frank, et al.
EFFECT OF PROPIVERINE ON CYTOCHROME P450 ENZYMES: A COCKTAIL INTERACTION STUDY IN HEALTHY VOLUNTEERS
Drug Metab. Dispos., December 1, 2005; 33(12): 1859 - 1866.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology